1. Skipka, G., Wieseler, B., Kaiser, T., Thomas, S., Bender, R., Windeler, J., Lange, S.: Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs. Biom J. Biometrische Zeitschrift. 58(1), 43–58 (2016).
https://doi.org/10.1002/bimj.201300274
2. IQWiG.: Documentation and evaluation of comments on the Draft of the General Methods 4.1. Institute for Quality and Efficiency in Health Care (2013).
https://www.iqwig.de/download/Dokumentation_und_Wuerdigung_der_Stellungnahmen_IQWiG_Methoden_4-1.pdf
. Accessed 6 Nov 2017
3. AMNOG.: Act to Reorganize the Pharmaceuticals’ Market in the SHI System (Arzneimittelneuordnungsgesetz-AMNOG) (2010).
http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl110s2262.pdf%27%5D__1431036981006
. Accessed 6 Nov 2017
4. IQWiG.: General Methods. Version 4.2 of 22 April 2015 (2015).
https://www.iqwig.de/download/IQWiG_General_Methods_Version_4-2_no_longer_valid.pdf
. Accessed 6 Nov 2017
5. Vach, W.: Quantifying the additional clinical benefit of new medicines: little-considerable-significant-6 remarks from a biometrician’s point of view]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)). 76(11), 757–762 (2014).
https://doi.org/10.1055/s-0033-1363682